Some structural considerations of the reactivity of vascular smooth muscle.
D000804:Angiotensin II / Q000494:pharmacology; D000818:Animals; D001011:Aorta / Q000033:anatomy & histology; D001808:Blood Vessels / Q000033:anatomy & histology*; D001949:Bretylium Compounds / Q000494:pharmacology; D002395:Catecholamines / Q000378:metabolism; D003042:Cocaine / Q000494:pharmacology; D004058:Diffusion; D004558:Electric Stimulation; D007099:Imipramine / Q000494:pharmacology; D008722:Methods; D009119:Muscle Contraction; D009130:Muscle, Smooth / Q000187:drug effects; D009431:Neural Conduction; D009451:Neuroeffector Junction / Q000187:drug effects / Q000378:metabolism*; D009538:Nicotine / Q000494:pharmacology; D009638:Norepinephrine / Q000378:metabolism / Q000494:pharmacology; D011651:Pulmonary Artery / Q000033:anatomy & histology; D011817:Rabbits; D012701:Serotonin / Q000494:pharmacology; D014316:Tritium; D014439:Tyramine / Q000494:pharmacology
D001949:Bretylium Compounds; D002395:Catecholamines; D014316:Tritium; D000804:Angiotensin II; D012701:Serotonin; D009538:Nicotine; D003042:Cocaine; D007099:Imipramine; D009638:Norepinephrine; D014439:Tyramine